In a much earlier posting in April 2004
I wrote about my work years ago with Dr. Dan Drucker to develop a derivative of the human hormone GLP-2 to treat short bowel syndrome. NPS Pharmaceuticals, the acquirer of Allelix, my employer at the time, just released this news release
about the positive results of a Phase 2 study and that they have now initiated a Phase 3 study. Yeah!!